Joshi Abhay 4
4 · Revance Therapeutics, Inc. · Filed Mar 18, 2019
Insider Transaction Report
Form 4
Joshi Abhay
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2019-03-14$4.20/sh+666$2,797→ 90,443 total - Exercise/Conversion
Stock Option (Right to buy)
2019-03-14−666→ 0 totalExercise: $4.20Exp: 2019-04-28→ Common Stock (666 underlying) - Tax Payment
Common Stock
2019-03-14$15.59/sh−166$2,588→ 90,277 total - Tax Payment
Common Stock
2019-03-15$15.45/sh−1,354$20,919→ 88,923 total
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the issuer on March 14, 2019, to satisfy tax withholding obligations that arose in connection with the exercise of a fully vested stock option for 666 shares.
- [F2]Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 11,750 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Dr. Joshi's Continuous Service on each vesting date.
- [F3]The option is fully vested.